Key Highlights
- Shares of INCY dropped 0.78% to close at $98.22 following Japanese regulatory approval for Minjuvi in DLBCL treatment.
- Japanese authorities authorized Minjuvi combined with lenalidomide for treating adults with relapsed DLBCL.
- Clinical data from L-MIND demonstrated a 58.8% overall response rate among transplant-ineligible patients.
- J-MIND study results revealed a 71.4% response rate in Japanese patients with DLBCL.
- This represents Minjuvi’s second regulatory clearance in Japan, following earlier approval for follicular lymphoma treatment.
Shares of Incyte Corporation (INCY) finished the session in negative territory despite receiving fresh Japanese regulatory clearance for Minjuvi in treating relapsed or refractory DLBCL. The stock settled at $98.22, representing a 0.78% decline, after briefly climbing above the $100 threshold earlier in the day. The shares showed resilience later in the session, recovering to hover around $99 before market close.
Japanese Health Ministry Broadens Minjuvi’s Treatment Scope
Incyte Biosciences Japan announced that the country’s health ministry has granted approval for Minjuvi in combination with lenalidomide for adult patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma. This regulatory clearance provides an additional therapeutic option for this challenging-to-treat lymphoma patient population in Japan.
Diffuse large B-cell lymphoma represents the most prevalent form of non-Hodgkin lymphoma. The condition impacts B lymphocytes and frequently demonstrates rapid progression when standard treatments prove ineffective. While numerous patients experience positive outcomes from first-line therapy, disease recurrence continues to pose significant clinical obstacles.
This approval specifically addresses patients who are unsuitable candidates for autologous stem cell transplantation. These individuals typically encounter restricted therapeutic alternatives following previous systemic treatments. Consequently, this Japanese authorization strengthens Incyte’s position in the oncology market and enhances treatment options for blood cancer patients.
Clinical Evidence Underpins Approval Decision
The regulatory approval draws upon evidence generated from the L-MIND and J-MIND clinical investigations. Both studies evaluated Minjuvi combined with lenalidomide in patients with relapsed or refractory DLBCL. The research concentrated on individuals deemed ineligible for autologous stem cell transplantation.
Results from the L-MIND study demonstrated an overall response rate of 58.8% as assessed by independent reviewers. Complete response rates achieved 41.3%, with partial responses representing 17.5% of outcomes. Notably, the median duration of response had not been reached following a minimum of 44 months of patient monitoring.
The J-MIND investigation yielded an overall response rate of 71.4% according to independent assessment. Complete responses comprised 45.2% of outcomes, while partial responses accounted for 26.2%. Incyte documented neutropenia and thrombocytopenia as the predominant adverse reactions observed during the trials.
Second Japanese Authorization Strengthens Minjuvi’s Market Position
This recent regulatory clearance represents the second approval Minjuvi has secured in Japan. The medication previously received authorization for use with rituximab and lenalidomide in treating relapsed or refractory follicular lymphoma. As such, this DLBCL approval extends the drug’s utility across two distinct lymphoma categories within the Japanese market.
Minjuvi functions as a humanized, Fc-modified monoclonal antibody designed to target the CD19 protein. The antibody mechanism initiates B-cell elimination through programmed cell death and immune-mediated responses. Incyte maintains worldwide development and marketing rights for tafasitamab through a licensing agreement with Xencor.
The therapy has secured regulatory authorizations in additional markets for comparable treatment scenarios. Within the United States, Monjuvi received approval for specific relapsed or refractory DLBCL patient populations. Throughout Europe, Minjuvi holds conditional marketing authorization for qualified adults diagnosed with relapsed or refractory DLBCL.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
